Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F13A1 | P00488 | 9/20 | 0.72 |
| ▸ | TGM2 | P21980 | 9/20 | 0.72 |
| ▸ | TGM1 | P22735 | 9/20 | 0.72 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CDK14 | O94921 | 1/20 | 0.52 |
| ▸ | CCNY | Q8ND76 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1868422 | 0.90 | F13A1 (0.70) | F13A1TGM2TGM1TGM3SMN1; SMN2 | |
| SCHEMBL1872793 | 0.88 | F13A1 (0.77) | F13A1TGM2TGM1SMN1; SMN2ALDH1A1 | |
| SCHEMBL1872963 | 0.88 | F13A1 (0.80) | F13A1TGM2TGM1TGM3SMN1; SMN2 | |
| SCHEMBL1874713 | 0.87 | F13A1 (0.80) | F13A1TGM2TGM1TGM3SMN1; SMN2 | |
| SCHEMBL1872126 | 0.85 | TGM2 (0.75) | F13A1TGM2TGM1TGM3ALDH1A1 | |
| SCHEMBL1870338 | 0.84 | TGM2 (1.00) | F13A1TGM2TGM1TGM3 | |
| SCHEMBL1867594 | 0.84 | TGM2 (0.80) | F13A1TGM2TGM1TGM3ALDH1A1 | |
| SCHEMBL1871756 | 0.84 | F13A1 (0.77) | F13A1TGM2TGM1TGM3SMN1; SMN2 | |
| SCHEMBL1869977 | 0.82 | F13A1 (0.68) | F13A1TGM2TGM1SMN1; SMN2ALDH1A1 | |
| SCHEMBL1869959 | 0.82 | F13A1 (0.70) | F13A1TGM2TGM1TGM3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946197-B2 | Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2015-02-03 | — | — | US | claimed |
| US-20130116216-A1 | TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | EVOTEC (UK) LTD. (GB) | 2013-05-09 | — | — | US | claimed |
| WO-2011060321-A1 | TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI, INC. (US) | 2011-05-19 | — | — | WO | claimed |
| US-8946197-B2 | Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946197-B2 | Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946197-B2 | Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20130116216-A1 | TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | EVOTEC (UK) LTD. (GB) | 2013-05-09 | — | — | US | disclosed |
| US-20130116216-A1 | TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | EVOTEC (UK) LTD. (GB) | 2013-05-09 | — | — | US | disclosed |
| US-20130116216-A1 | TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | EVOTEC (UK) LTD. (GB) | 2013-05-09 | — | — | US | disclosed |
| WO-2011060321-A1 | TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI, INC. (US) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116216-A1 | TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | HTT, TGM2, GRN | F13A1 1540/4885TGM2 2/4885TGM1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.